We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+52.07%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$7.74B
AUM Growth
+$2.03B
Cap. Flow
-$20.7M
Cap. Flow %
-0.27%
Top 10 Hldgs %
72.43%
Holding
35
New
5
Increased
11
Reduced
11
Closed
3

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$103M
2
GPCR icon
Structure Therapeutics
GPCR
+$103M
3
SLNO
Soleno Therapeutics
SLNO
+$39.1M
4
OCUL icon
Ocular Therapeutix
OCUL
+$34.1M
5
MRUS
Merus
MRUS
+$25.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$122M
2
UTHR icon
United Therapeutics
UTHR
+$117M
3
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$112M
4
BPMC
Blueprint Medicines
BPMC
+$48.1M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$27.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MNKD icon
26
MannKind Corp
MNKD
$1.32B
$24M 0.31%
4,468,877
-1,381,123
-24% -$6.06M
MLTX icon
27
MoonLake Immunotherapeutics
MLTX
$1.55B
$14.3M 0.19%
2,000,000
-2,150,000
-52% -$112M
BCRX icon
28
BioCryst Pharmaceuticals
BCRX
$2.4B
$9.49M 0.12%
1,250,000
-3,250,000
-72% -$27.1M
WHWK
29
Whitehawk Therapeutics
WHWK
$235M
$5.41M 0.07%
2,849,402
– –
TNGX icon
30
Tango Therapeutics
TNGX
$4.41B
$4.58M 0.06%
+545,000
New +$3.69M
UTHR icon
31
CALL
United Therapeutics
UTHR
$23.1B
$4.44M 0.06%
+200,000
New +$67.3M
GPCR icon
32
CALL
Structure Therapeutics
GPCR
$3.78B
$2.24M 0.03%
+250,000
New +$4.98M
BPMC
33
DELISTED
Blueprint Medicines
BPMC
– –
-375,000
Closed -$48.1M
GLUE icon
34
Monte Rosa Therapeutics
GLUE
$1.34B
– –
-3,725,000
Closed -$16.8M
RARE icon
35
Ultragenyx Pharmaceutical
RARE
$2.55B
– –
-330,000
Closed -$12M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Avoro Capital Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Avoro Capital Advisors held 35 positions worth $7.74B, up 35% from $5.71B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Avoro Capital Advisors's Q3 2025 filing shows 5 new, 11 increased, 11 reduced and 3 closed positions. Its largest new stake was Structure Therapeutics: 5,155,555 shares worth $144M. The largest sale was argenx, an estimated $122M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

  • Avoro Capital Advisors's largest Q3 2025 buy was Structure Therapeutics: 5,155,555 shares worth $144M.
  • Avoro Capital Advisors added most to Centessa Pharmaceuticals in Q3 2025, an estimated $103M increase.
  • Avoro Capital Advisors's biggest Q3 2025 reduction was argenx, cutting an estimated $122M.
  • Avoro Capital Advisors fully exited Blueprint Medicines in Q3 2025, selling an estimated $48.1M.
  • Avoro Capital Advisors's ten largest holdings make up 72% of its $7.74B portfolio in Q3 2025.
  • Avoro Capital Advisors opened 5 new positions and closed 3 in Q3 2025.
  • Avoro Capital Advisors's portfolio value rose 35% quarter-over-quarter to $7.74B.

Based on Avoro Capital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.